- Anaesthesia adjunct:
- Preoperative: IM 4mcg/kg 30-60 min before surgery
- For reduction of secretions
- Preoperative: IM 4mcg/kg 30-60 min before surgery
-
- Intraoperative: IV 0.1mg
- May repeat every 2-3min
- For reversal of bradycardia, vagal reflexes
- Intraoperative: IV 0.1mg
- Neuromuscular blockade reversal:
- IV 0.2mg IV per 1mg of neostigmine or 5mg of pyridostigmine administered
- IV 0.2mg IV per 1mg of neostigmine or 5mg of pyridostigmine administered
- Adjunct to treatment of peptic ulcer:
- PO 1-2mg BD/TDS
- Start: PO 1mg TDS
- Max: 8mg/day
- PO 1-2mg BD/TDS
-
- IM/IV 0.1-0.2mg TDS/QID
- Max: 0.8mg/day
- Space doses 4 hrs apart
- IM/IV 0.1-0.2mg TDS/QID
- Antisialogogue (Off-label):
- PO 1-2mg BD/TDS PRN
- Max: 8mg/day
- Injectable product may be given PO
- PO 1-2mg BD/TDS PRN
-
- SC/IM/IV 0.1-0.2mg every 4-8 hrs PRN
- Max: 0.8mg/day
- Max: 0.8mg/day
- SC/IM/IV 0.1-0.2mg every 4-8 hrs PRN
- Hyperhidrosis (Off-label)
- PO 1-2mg BD/TDS PRN
- Start: PO 1mg BD
- Max: 8 mg/day
- PO 1-2mg BD/TDS PRN
- Drooling (Off-label)
- PO 0.1mg/kg BD/TDS
- Max 8mg/day
- Injection:
- 2mg/mL
- Tablet:
- 1mg
- 2mg
- High fat food reduces PO bioavailability
- Administer IV at a rate of 0.2mg over 1-2 min
Anticholinergic (antimuscarinic) agent
It inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation.
- Xerostomia
- Vomiting
- Constipation
- Flushing
- Nasal congestion
- Headache
- Sinusitis
- URI
- Urinary retention
- Drowsiness
- Photophobia
- Lactation suppression
- Hypersensitivity to drug or ingredient
- Neonates (benzyl alcohol-containing inj form)
- Angle-closure glaucoma
- Myasthenia gravis
- Obstructive uropathy
- Acute hemorrhage with unstable cardiovascular status
- GI ulcer or bleeding
- GI obstruction
- GI motility disorder
- Intestinal atony (elderly or debilitated pts)
- Paralytic ileus
- Toxic megacolon
- Toxic megacolon history
- Inflammatory or infectious colitis
- Potassium chloride
- Potassium citrate
- Umeclidinium bromide/vilanterol inhaled
Drug Status
Availability | Prescription only |
Pregnancy | Weigh risk vs benefit |
Breastfeeding | Weigh risk vs benefit; may cause lactation suppression |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Glycopyrronium Bromide | 200mcg/mL | Injection | 10’s | Macarthys Labs | Laborex Kenya |